LEXICON PHARMACEUTICALS, INC. Restructuring and Related Cost, Cost Incurred to Date (Deprecated 2014-01-31)
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Restructuring and Related Cost, Cost Incurred to Date (Deprecated 2014-01-31) of $4.00 million for the 3-month period ending 2014-03-31, per its 10-Q filed 2014-05-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostCostIncurredToDate · last filed 2014-05-08
- LEXICON PHARMACEUTICALS, INC. restructuring and related cost, cost incurred to date (deprecated 2014-01-31) for the quarter ending 2014-03-31 was $4.00M.
| Period end | Restructuring and Related Cost, Cost Incurred to Date (Deprecated 2014-01-31) 3 month |
|---|---|
| 2014-03-31 | $4.00M 10-Q · filed 2014-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |